1. Medtech Insight
  2. >>Geography

Singapore & Beyond: Asian Medtech Associations Regulatory Networking November 2017, Part 2

 
• By Ashley Yeo

In the second of two Asian Medtech Associations Regulatory Networking discussions this month, we focus on regulatory reforms in Singapore, and updates on Indonesia, the Philippines and Vietnam from recent regional regulatory meetings. This series is hosted by Medtech Insight and sponsored by the Asia Regulatory and Quality Consultancy (ARQon), the Asia Regulatory Professionals Association (ARPA), and Medtronic.

[Editors' note: In November, Medtech Insight sat down with Asia-based regulatory experts to discuss updates from the region in the second Medtech Associations Regulatory Networking event, sponsored by Asia Regulatory and Quality Consultancy (ARQon) and the Asia Regulatory Professional Association (ARPA). The main takeaways from the conversation on Singapore and updates from the recent APACMed regulatory track, are detailed below. The first part of this month's conversation covered Malaysia.]

Broad-scale medtech regulatory change is under way in Singapore, as part of a program designed to speed highly-innovative products into circulation and remove certain procedural steps for lower-risk products. (Also...

More from Asia

More from Geography

Guardant Health Launches Germline Hereditary Cancer Test

 
• By Natasha Barrow

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 
• By Natasha Barrow

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.